Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 795.15 +10.30 (1.31%)
Previous Close $784.85    52 Week High $592.36 
Open $786.03    52 Week Low $325.35 
Day High $801.44    P/E 208.70 
Day Low $779.96    EPS $3.81 
Volume 371,814